Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative therapies for cancer treatment. Founded in 2007, the company has made significant strides in the oncology sector, particularly with its lead product, onvansertib, which targets specific cancer pathways to enhance treatment efficacy. With a strong presence in major operational regions, Cardiff Oncology is dedicated to advancing precision medicine and improving patient outcomes. The company has garnered attention for its unique approach to targeting KRAS mutations, positioning itself as a leader in the competitive oncology landscape. Notable achievements include successful clinical trials that underscore the potential of its therapies, solidifying Cardiff Oncology's reputation as a key player in the fight against cancer.
DitchCarbon Score
How does Cardiff Oncology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cardiff Oncology, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cardiff Oncology, Inc.'s reported carbon emissions
Cardiff Oncology, Inc., headquartered in the US, currently does not have publicly available data on its carbon emissions, as there are no reported figures for emissions in kg CO2e. Additionally, the company has not outlined any specific reduction targets or initiatives related to climate commitments. In the absence of concrete emissions data or defined climate pledges, it is unclear how Cardiff Oncology is addressing its environmental impact. As the industry increasingly prioritises sustainability, it will be important for the company to establish and communicate its climate strategies moving forward.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cardiff Oncology, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
